# Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201

> **NCT05088369** · PHASE1 · COMPLETED · sponsor: **Syneos Health** · enrollment: 53 (actual)

## Conditions studied

- Ulcerative Colitis
- Crohn's Disease

## Interventions

- **DRUG:** HM201
- **DRUG:** Placebo
- **DRUG:** HM201
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05088369
- **Lead sponsor:** Syneos Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-11
- **Primary completion:** 2022-12-19
- **Final completion:** 2022-12-19
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2023-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05088369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05088369, "Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05088369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*